Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999569 · ClinicalTrials.gov registry record · Phase 4
The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT01999569 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 10 participants.
The verdict
NCT01999569, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of the study is to establish that sustained estrogen levels are the driving force for the LH surge, and are thereby necessary for ovulation to occur. We predict that by reducing levels of circulating estrogen, letrozole, an aromatase inhibitor, will inhibit ovulation from occurring.
Interventions
- DRUG Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01999569
The ClinicalTrials.gov registry entry for NCT01999569 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Letrozole is the first listed.
NCT01999569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01999569 about?
NCT01999569 is a clinical study titled "The Role of Estrogen in Luteinizing Hormone Surge and Ovulation". The purpose of the study is to establish that sustained estrogen levels are the driving force for the LH surge, and are thereby necessary for ovulation to occur. We predict that by reducing levels of circulating estrogen, letrozole, an aromatase inhibitor, will inhibit ovulation from occurring.
What is the current status of trial NCT01999569?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2007-04. Estimated completion is 2008-05.
What interventions are being tested in trial NCT01999569?
The interventions under investigation include: Letrozole (DRUG).
Who is sponsoring clinical trial NCT01999569?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.